Correspondence 0001193125-22-286390 from Omega Therapeutics, Inc. (OMGA) (CIK 0001850838)
Omega Therapeutics, Inc. (OMGA) (CIK 0001850838)
Date: Nov. 16, 2022 · CIK: 0001850838 · Accession: 0001193125-22-286390
AI Filing Summary & Sentiment
File numbers found in text: 333-268254
Letter
Re: Omega Therapeutics, Inc.
November 16, 2022
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
Filed November 8, 2022
Registration No. 333-268254
To whom it may concern:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on November 18, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Omega Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Wesley Holmes of Latham & Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Omega Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 16, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Omega Therapeutics, Inc. Registration Statement on Form S-3 Filed November 8, 2022 Registration No. 333-268254 To whom it may concern: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on November 18, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Omega Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Wesley Holmes of Latham & Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Omega Therapeutics, Inc. By: /s/ Mahesh Karande Mahesh Karande President and Chief Executive Officer cc: Joshua Reed, Chief Financial Officer, Omega Therapeutics, Inc. Ling Zeng, Esq., Chief Legal and Administrative Officer, Omega Therapeutics, Inc. Wesley Holmes, Esq., Latham & Watkins LLP Peter Handrinos, Esq., Latham & Watkins LLP